Wutzler P - Search Results

1

Inhibition of nuclear factor kappa B activation reduces Coxsackievirus B3 replication in lymphoid cells.

Sobotta K, Wilsky S, Althof N, Wiesener N, Wutzler P, Henke A. Sobotta K, et al. Among authors: wutzler p. Virus Res. 2012 Feb;163(2):495-502. doi: 10.1016/j.virusres.2011.11.014. Epub 2011 Nov 25. Virus Res. 2012. PMID: 22138672

2

Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes.

Jarasch-Althof N, Wiesener N, Schmidtke M, Wutzler P, Henke A. Jarasch-Althof N, et al. Among authors: wutzler p. Viral Immunol. 2010 Aug;23(4):369-76. doi: 10.1089/vim.2010.0018. Viral Immunol. 2010. PMID: 20712481

3

Therapy of experimental influenza virus infection with pyrrolidine dithiocarbamate.

Wiesener N, Zimmer C, Jarasch-Althof N, Wutzler P, Henke A. Wiesener N, et al. Among authors: wutzler p. Med Microbiol Immunol. 2011 May;200(2):115-26. doi: 10.1007/s00430-010-0182-x. Epub 2010 Dec 21. Med Microbiol Immunol. 2011. PMID: 21174118

4

Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication.

Wilsky S, Sobotta K, Wiesener N, Pilas J, Althof N, Munder T, Wutzler P, Henke A. Wilsky S, et al. Among authors: wutzler p. Arch Virol. 2012 Feb;157(2):259-69. doi: 10.1007/s00705-011-1164-z. Epub 2011 Nov 11. Arch Virol. 2012. PMID: 22075919

5

Antiviral effects of pan-caspase inhibitors on the replication of coxsackievirus B3.

Martin U, Jarasch N, Nestler M, Rassmann A, Munder T, Seitz S, Zell R, Wutzler P, Henke A. Martin U, et al. Among authors: wutzler p. Apoptosis. 2007 Mar;12(3):525-33. doi: 10.1007/s10495-006-0015-y. Epub 2007 Jan 9. Apoptosis. 2007. PMID: 17211569

6

Influence of pan-caspase inhibitors on coxsackievirus B3-infected CD19+ B lymphocytes.

Jarasch N, Martin U, Zell R, Wutzler P, Henke A. Jarasch N, et al. Among authors: wutzler p. Apoptosis. 2007 Sep;12(9):1633-43. doi: 10.1007/s10495-007-0084-6. Apoptosis. 2007. PMID: 17520192

7

Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.

Henke A, Jarasch N, Martin U, Wegert J, Wildner A, Zell R, Wutzler P. Henke A, et al. Among authors: wutzler p. Int J Med Microbiol. 2008 Jan;298(1-2):127-34. doi: 10.1016/j.ijmm.2007.08.010. Epub 2007 Sep 25. Int J Med Microbiol. 2008. PMID: 17897883 Review.

8

Characterization of the protective capability of a recombinant coxsackievirus B3 variant expressing interferon-gamma.

Henke A, Jarasch N, Martin U, Zell R, Wutzler P. Henke A, et al. Among authors: wutzler p. Viral Immunol. 2008 Mar;21(1):38-48. doi: 10.1089/vim.2007.0077. Viral Immunol. 2008. PMID: 18355121

9

Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis.

Henke A, Jarasch N, Wutzler P. Henke A, et al. Among authors: wutzler p. Expert Rev Vaccines. 2008 Dec;7(10):1557-67. doi: 10.1586/14760584.7.10.1557. Expert Rev Vaccines. 2008. PMID: 19053211 Free article. Review.

10

Analysis of different DNA vaccines for protection of experimental influenza A virus infection.

Wiesener N, Schütze T, Lapp S, Lehmann M, Jarasch-Althof N, Wutzler P, Henke A. Wiesener N, et al. Among authors: wutzler p. Viral Immunol. 2011 Aug;24(4):321-30. doi: 10.1089/vim.2011.0001. Viral Immunol. 2011. PMID: 21830903

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

324 results

Search Page

Filters